Lenalidomidă Stada

Lenalidomide, the active ingredient in Lenalidomidă Stada, is an immunomodulatory imide drug (IMiD) presented as an oral tablet for oral use. It is indicated for the treatment of multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomidă Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution, shipping products with appropriate documentation to ensure seamless import and clinical use.

Lenalidomidă Stada is employed in hematologic malignancies that involve abnormal plasma‑cell proliferation.

Multiple myeloma: reduces tumor burden and prolongs progression‑free survival. Myelodysplastic syndromes with del(5q): improves blood counts and lowers transfusion dependence. Mantle cell lymphoma: contributes to disease control when used in combination regimens.

Lenalidomidă Stada may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Fatigue or weakness. - Nausea, vomiting or loss of appetite. - Diarrhea or constipation. - Rash or pruritus. - Low neutrophil count (neutropenia). - Low platelet count (thrombocytopenia).

Serious or Rare Side Effects: - Thromboembolic events such as deep‑vein thrombosis or pulmonary embolism. - Severe neutropenia or infections requiring hospitalization. - Secondary primary malignancies, including acute leukemias.

When prescribing Lenalidomidă Stada, clinicians should consider several safety measures to minimize risk.

Pregnancy risk: contraindicated in pregnancy (Category X); ensure effective contraception. Thromboembolism: assess individual risk and consider prophylactic anticoagulation. Hematologic monitoring: perform regular complete blood counts to detect neutropenia or thrombocytopenia. Renal impairment: evaluate renal function and adjust dosing as needed. Drug interactions: review concomitant medications for CYP or anticoagulant effects. Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Lenalidomidă Stada can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin) – may markedly reduce lenalidomide exposure. - Anticoagulants such as warfarin – increased risk of bleeding. - Immunosuppressants (e.g., cyclosporine) – may heighten toxicity.

Moderate Interactions (Monitor Closely): - Antiplatelet agents (e.g., aspirin) – monitor for additive bleeding risk. - Live attenuated vaccines – avoid due to potential immunosuppression. - Other IMiDs (e.g., thalidomide, pomalidomide) – concurrent use is not recommended.